United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00.
• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total transaction of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total transaction of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total value of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total value of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total value of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $421.80, for a total value of $9,490,500.00.

United Therapeutics Stock Down 0.7%

Shares of UTHR traded down $3.15 during trading hours on Tuesday, reaching $476.36. The company’s stock had a trading volume of 299,097 shares, compared to its average volume of 580,494. The company has a 50 day moving average of $454.01 and a two-hundred day moving average of $369.93. The firm has a market cap of $20.51 billion, a price-to-earnings ratio of 18.05, a P/E/G ratio of 4.86 and a beta of 0.86. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the prior year, the business earned $6.39 EPS. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the company. Clearstead Advisors LLC grew its stake in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 23 shares during the last quarter. Bessemer Group Inc. boosted its holdings in United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 28 shares during the period. Archer Investment Corp grew its position in shares of United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 31 shares during the last quarter. F m Investments LLC increased its stake in shares of United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares during the period. Finally, HB Wealth Management LLC lifted its position in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on UTHR. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 1st. Oppenheimer raised their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a report on Wednesday, October 29th. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.